Compugen, our long-term client, a publicly traded company on both the Nasdaq and Tel Aviv Stock Exchange, is dedicating itself to advancing cancer immunotherapy treatments.
In support of Compugen’s relentless commitment to tackling some of the biggest challenges in medicine, we had the great pleasure of representing Compugen in the recent completion of a US$ 50 Million public offering of shares on the Nasdaq, via an At-The-Market (ATM) sale mechanism.
Well done to our team led by Partners Shelly Blatt Zak and Ivor Krumholtz, together with Associates Neri Azari and Ofra Leventer, and Partner Ibrahim Atrash from our Tax practice.
